These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 24614622)

  • 1. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
    Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
    PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
    Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
    Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
    Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
    Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
    Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
    Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
    Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
    de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
    Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    Lai A; Kharbanda S; Pope WB; Tran A; Solis OE; Peale F; Forrest WF; Pujara K; Carrillo JA; Pandita A; Ellingson BM; Bowers CW; Soriano RH; Schmidt NO; Mohan S; Yong WH; Seshagiri S; Modrusan Z; Jiang Z; Aldape KD; Mischel PS; Liau LM; Escovedo CJ; Chen W; Nghiemphu PL; James CD; Prados MD; Westphal M; Lamszus K; Cloughesy T; Phillips HS
    J Clin Oncol; 2011 Dec; 29(34):4482-90. PubMed ID: 22025148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
    Szeliga M
    Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.